Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells
Sylvia Janetzki(Yale University), Axel Hoos(GlaxoSmithKline (United States)), Judy Caterini(Sanofi (Canada)), Jeffrey R. Currier(Walter Reed Army Institute of Research), Eckhart Kaempgen(Comprehensive Cancer Center Erlangen), Cedrik M. Britten(Johannes Gutenberg University Mainz), Sjoerd H. van der Burg(Leiden University Medical Center), Victor Costa de Souza(Pfizer (United States)), Guido Ferrari(Duke University), Peter Hayes(International AIDS Vaccine Initiative), Volker Lennerz(Johannes Gutenberg University Mainz), Kopek Nihlmark(Mabtech (Sweden)), Leah Price(Cwm Taf University Health Board), Cécile Gouttefangeas(University of Tübingen)
Cited by 52
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2015|1.3k
Therapeutic cancer vaccines
|Journal of Clinical Investigation|2015|1.1k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803